Data as of Mar 11
| -0.08 / -2.29%|
The 3 analysts offering 12-month price forecasts for Neogenomics Inc have a median target of 5.00, with a high estimate of 6.00 and a low estimate of 5.00. The median estimate represents a +46.20% increase from the last price of 3.42.
The current consensus among 5 polled investment analysts is to Buy stock in Neogenomics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.